Biliary Dyskinesia
9
3
3
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
22.2%
2 terminated out of 9 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia
Feasibility and Utility of Artificial Intelligence (AI) / Machine Learning (ML) - Driven Advanced Intraoperative Visualization and Identification of Critical Anatomic Structures and Procedural Phases in Laparoscopic Cholecystectomy
Gallbladder Cryoablation in High-Risk Patients
Transvaginal Cholecystectomy Using Endoscopic Assistance
Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy
Single-Incision Laparoscopic Cholecystectomy Versus Traditional Laparoscopic Cholecystectomy
Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Cholecystectomy
Ultrasound for Diagnosis of Biliary Dyskinesia